A Review of the Therapeutic Potential of the Cysteinyl Leukotriene Antagonist Montelukast in the Treatment of Bronchiolitis Obliterans Syndrome Following Lung and Hematopoietic-Stem Cell Transplantation and Its Possible Mechanisms Publisher Pubmed



Kordjazy N¹ ; Amini S² Show Affiliations
Source: Therapeutic Advances in Respiratory Disease Published:2024

Abstract

Lung and hematopoietic stem cell transplantation are therapeutic modalities in chronic pulmonary and hematological diseases, respectively. One of the complications in these patients is the development of bronchiolitis obliterans syndrome (BOS). The efficacy and safety of available treatment strategies in BOS remain a challenge. A few mechanisms have been recognized for BOS in lung transplant and graft-versus-host disease (GVHD) patients involving the TH-1 and TH-2 cells, NF-kappa B, TGF-b, several cytokines and chemokines, and cysteinyl leukotrienes (CysLT). Montelukast is a highly selective CysLT receptor antagonist that has been demonstrated to exert anti-inflammatory and anti-fibrotic effects in abundant experiments. One area of interest for the use of montelukast is lung transplants or GVHD-associated BOS. Herein, we briefly review data regarding the mechanisms involved in BOS development and montelukast administration as a treatment modality for BOS, and finally, the possible relationship between CysLTs antagonism and BOS improvement will be discussed. © The Author(s), 2024.